$3.10
5.44% yesterday
Nasdaq, Apr 02, 10:00 pm CET
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Inventiva - ADR Stock price

$3.10
+0.14 4.73% 1M
+1.22 64.90% 6M
+0.96 44.86% YTD
-0.53 14.60% 1Y
-8.66 73.64% 3Y
-10.32 76.90% 5Y
-10.32 76.90% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.16 5.44%
ISIN
US46124U1079
Symbol
IVA
Sector
Industry

Key metrics

Market capitalization $296.01m
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 29.72
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -47.32%
Revenue (TTM) Revenue $9.96m
EBIT (operating result TTM) EBIT $-110.44m
EPS (TTM) EPS $-3.33
P/E forward negative
P/S forward 31.32
EV/Sales forward 36.39
Short interest 3.06%
Show more

Is Inventiva - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Inventiva - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Inventiva - ADR forecast:

10x Buy
100%

Analyst Opinions

10 Analysts have issued a Inventiva - ADR forecast:

Buy
100%

Financial data from Inventiva - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
9.96 9.96
47% 47%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
39% 39%
192%
- Research and Development Expense 99 99
15% 15%
997%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -110 -110
5% 5%
-1,109%
Net Profit -199 -199
67% 67%
-2,001%

In millions USD.

Don't miss a Thing! We will send you all news about Inventiva - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inventiva - ADR Stock News

Neutral
GlobeNewsWire
one day ago
Daix (France), New York City (New York, United States), April 1, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”) and other diseases with significant unmet medical needs, today annou...
Neutral
Seeking Alpha
7 days ago
Inventiva S.A. (NASDAQ:IVA ) Q4 2024 Earnings Call March 27, 2025 8:00 AM ET Company Participants Frédéric Cren - CEO Jean Volatier - CFO Pierre Broqua - CSO Conference Call Participants Unidentified Analyst - TD Cowen Unidentified Analyst - Jefferies & Co. Annabel Samimy - Stifel Ed Arce - HC Wainwright Jacob Mekhael - KBC Securities Rami Katkhuda - LifeSci Capital Unidentified Analyst - UBS O...
Neutral
GlobeNewsWire
8 days ago
Daix (France), New York City (New York, United States), March 26, 2025 – Inventiva (Euronext Paris and NASDAQ: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (“MASH”), and other diseases with significant unmet medical needs, today reported its finan...
More Inventiva - ADR News

Company Profile

Inventiva SA engages in the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis and related diseases. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centred on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.

Head office France
CEO Frédéric Cren
Founded 2011
Website www.inventivapharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today